Analyst Reco. Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
20.89 ^USD	-0.52%		-0.52%	+86.52%

06-24	Harrow, Inc.(NasdaqGM:HROW) added to S&P Pharmaceuticals Select Industry Index	CI
06-21	Craig-Hallum Adjusts Price Target on Harrow Health to $30 From $26, Buy Rating Maintained	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Craig-Hallum Adjusts Price Target on Harrow Health to $30 From $26, Buy Rating Maintained	06-21	MT
Lake Street Raises Price Target on Harrow to $25 From $20, Maintains Buy Rating	06-03	MT
B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	05-15	MT
Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	04-11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	03-22	MT
B. Riley Lowers Harrow's PT to $30 From $45 After Lower-Than-Expected Q3 Results, Reduced Q4 Guidance; Keeps Buy Rating	11-14	MT
B. Riley Raises Harrow Health's PT to $45 From $42 on Heels of Announced Transactions With Santen, Novaliq; Keeps Buy Rating	20/07/23	MT
B. Riley Raises Harrow Health's Price Target to $42 From $24, Keeps Buy Rating	04/05/23	MT
Lake Street Adjusts Price Target on Harrow Health to $37 From $24, Maintains Buy Rating	17/04/23	MT
B. Riley Lifts Harrow Health's PT to $24 From $22 Accounting for Additional Incremental Revenues From Fab-Five Products, Ramp Up of IHEEZO Sales Trajectory in 2024; Keeps Buy Rating	27/03/23	MT
B. Riley Raises Harrow Health's PT to $22 From $17 on Heels of Acquisition of 5 New Ophthalmology Products, Keeps Buy Rating	05/01/23	MT
B. Riley Securities Resumes Harrow Health at Buy with $17 Price Target, Says Well-Positioned to Maintain Robust Momentum	08/09/22	MT
B. Riley Raises Harrow Health's Price Target to $20 from $17 After Higher-than-Expected Q1 Revenue, Keeps Buy Rating	20/05/22	MT
HARROW HEALTH : B. Riley Resumes Harrow Health at Buy with $16 PT, Says Well-Positioned to Maintain Momentum with Recent Q2 Beat, M&A Execution	14/10/21	MT
HARROW HEALTH : Aegis Capital Starts Harrow Health at Buy with $15 Price Target	24/09/21	MT
Harrow Health : Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones (Form 8-K)	14/06/21	PU
HARROW HEALTH : B. Riley Adjusts Harrow Health's Price Target to $14 From $12, Keeps Buy Rating	04/01/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer